SCHEMBL3325142

SCHEMBL3325142

Cc1cn(C[C@H]2CN(c3ccc(Br)cn3)C(=O)O2)nn1

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAOA P21397 10/20 0.50
GRM5 P41594 5/20 0.41
KCNH2 Q12809 2/20 0.36
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3328153 0.81 MAOA (0.49) MAOAKCNH2MAOB
SCHEMBL17286801 0.79 GRM5 (0.48) MAOAGRM5MAOB
SCHEMBL17286803 0.79 GRM5 (0.48) MAOAGRM5MAOB
SCHEMBL14410638 0.78 MAOA (0.58) MAOAKCNH2MAOB
SCHEMBL15856197 0.78 MAOA (0.47) MAOAGRM5MAOB
SCHEMBL3327072 0.78 MAOA (0.47) MAOAGRM5MAOB
SCHEMBL15856168 0.78 MAOA (0.47) MAOAGRM5MAOB
SCHEMBL3325784 0.77 GRM5 (0.46) GRM5
SCHEMBL15856178 0.77 GRM5 (0.46) MAOAGRM5MAOB
SCHEMBL7304594 0.76 GRM5 (0.65) MAOAGRM5MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137243-A1 Oxazolidinone And/Or Isoxazoline As Antibacterial Agents ASTRAZENECA AB (SE) 2010-06-03 US disclosed
US-20100137243-A1 Oxazolidinone And/Or Isoxazoline As Antibacterial Agents ASTRAZENECA AB (SE) 2010-06-03 US disclosed
US-7396847-B2 Oxazolidinone and/or isoxazoline as antibacterial agents ASTRAZENECA AB (SE) 2008-07-08 US disclosed
US-7396847-B2 Oxazolidinone and/or isoxazoline as antibacterial agents ASTRAZENECA AB (SE) 2008-07-08 US disclosed
US-7396847-B2 Oxazolidinone and/or isoxazoline as antibacterial agents ASTRAZENECA AB (SE) 2008-07-08 US disclosed
EP-1427711-B1 OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2005-07-13 EP disclosed
US-20050107435-A1 Oxazolidinone and/or isoxazoline as antibacterial agents ASTRAZENECA AB (SE) 2005-05-19 US disclosed
EP-1427711-A1 OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS AstraZeneca AB (SE) 2004-06-16 EP disclosed
WO-2003022824-A1 OXAZOLIDINONE AND/OR ISOXAZOLINE AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2003-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137243-A1 Oxazolidinone And/Or Isoxazoline As Antibacterial Agents CYP8B1, HRH2, CYP2W1 MAOA 482/4885GRM5 2992/4885KCNH2 1898/4885
US-20050107435-A1 Oxazolidinone and/or isoxazoline as antibacterial agents CYP8B1, CYP2W1, HRH2 MAOA 800/4885GRM5 2838/4885KCNH2 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.